Celltrion Healthcare, First Time Surpassing 500 Billion KRW in 1Q Sales

21% Increase Compared to Same Period Last Year
Operating Profit Up 13.3% · Net Profit Up 24.1%

Celltrion Healthcare surpassed 500 billion KRW in sales for the first time in any first quarter in its history.

Celltrion Healthcare CI. [Image provided by Celltrion Healthcare]

Celltrion Healthcare announced on the 12th that its consolidated sales for the first quarter of this year reached 503.6 billion KRW, a 21.1% increase compared to the same period last year. Operating profit for the same period rose 13.3% to 51 billion KRW, and net profit increased 24% to 54.1 billion KRW.

The company explained that, due to the nature of its business, it achieved strong performance by surpassing 500 billion KRW in sales for the first time in the relatively off-season first quarter. Operating profit also improved as prescriptions for highly profitable products continued to expand. The operating profit margin was recorded at 10.1%. Net profit was influenced by an increase in pre-tax profit due to foreign exchange gains from the weakening of the Korean won.

Celltrion Healthcare Q1 Performance. [Image provided by Celltrion Healthcare]

In particular, the company stated that performance improved as prescriptions of Inflectra (generic name infliximab) increased in the North American region, and sales of Remsima SC and Yuflyma (generic name adalimumab) expanded in Europe.

As of March, Inflectra maintained its position as the top prescribed biosimilar with a market share of 31.4%. Remsima SC also saw a 65% increase in European sales in the first quarter compared to the same period last year. Yuflyma recorded more than 50% of last year’s annual sales in just the first quarter of this year, continuing its upward trend. Along with this, after expanding the direct sales system to all products in Europe last year, the recovery in order performance for Truxima (generic name rituximab) and Herzuma (generic name trastuzumab) also contributed to the improved results. In particular, Herzuma’s European sales in the first quarter more than doubled compared to the same period last year.

Celltrion Healthcare announced plans to strengthen its portfolio through new product launches. First, it plans to launch Yuflyma in the U.S. market in the second half of this year. Additionally, as achievements such as winning bids in Italy and expanding prescriptions in France continue in the European market, the company stated it will leverage this experience to further expand the market.

A Celltrion Healthcare official said, "We achieved record-breaking first-quarter sales results as follow-up products continued stable growth not only in the highly profitable North American region but also in Europe. We will continue to sustain prescription performance globally and maintain stable growth based on a more diversified portfolio."

This content was produced with the assistance of AI translation services.